Home » OncoGenex Grabs $60 Million Upfront From Teva for Rights to Cancer Drug
OncoGenex Grabs $60 Million Upfront From Teva for Rights to Cancer Drug
Bothell, WA-based OncoGenex Pharmaceuticals announced Monday it has clinched $60 million in upfront payments from Israel-based Teva Pharmaceutical for
the right to co-develop an experimental prostate cancer drug that has been shown to prolong patients’ lives in a small study.
Xconomy
Xconomy
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May